atherosclerosis therapy (Aventis Gencell/INSERM)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameatherosclerosis therapy (Aventis Gencell/INSERM)

Drug Alias Nameapolipoprotein gene therapy (Aventis Gencell/INSERM)apoE (Aventis Gencell)apoA-IV gene therapy (RPR Gencell)atherosclerosis therapy (RPR Gencell/INSERM)

ClassificationCell and gene therapy > Gene therapy

Mechanisms of ActionApolipoprotein E agonists

TargetsApolipoprotein E

Therapy Area/IndicationsAtherosclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCentelion SAS

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCentelion SAS Inserm

Active IndicationsN/A

Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A